CLINICAL ROLE -
Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions
This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.
Read More